Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy (NCT06056830)

🧪 Interventions in This Study

• 64Cu-SAR-bisPSMA (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (31 Sites)

Showing the first 25 of 31 sites.

• University of Alabama Birmingham Hospital — Birmingham, Alabama
• Mayo Clinic- Phoenix — Phoenix, Arizona
• Arkansas Urology Research Center, LLC — Little Rock, Arkansas
• Urology Group of Southern California — Los Angeles, California
• Greater Los Angeles VA Medical Center — Los Angeles, California
• UC Irvine Health — Orange, California
• Stanford University Medical Center — Stanford, California
• Mayo Clinic- Jacksonville — Jacksonville, Florida
• Biogenix Molecular, LLC — Miami, Florida
• NorthShore University Health System, Glenbrook Hospital — Glenview, Illinois
• Indiana University School of Medicine — Indianapolis, Indiana
• Wichita Urology Group — Wichita, Kansas
• BAMF Health — Grand Rapids, Michigan
• Corewell Health — Grand Rapids, Michigan
• Mayo Clinic- Rochester — Rochester, Minnesota
• XCancer Omaha LLC — Omaha, Nebraska
• Mount Sinai Doctors Urology Faculty Practice — New York, New York
• Duke University Medical Center — Durham, North Carolina
• Urologic Specialists — Tulsa, Oklahoma
• Oregon Urology — Springfield, Oregon
• Carolina Urologic Research Center — Myrtle Beach, South Carolina
• Urology Associates of Nashville — Nashville, Tennessee
• Urology Clinics of North Texas — Dallas, Texas
• University of Texas Southwestern Medical Center — Dallas, Texas
• The Urology Place — San Antonio, Texas

📞 Contact the Study Coordinator

Phone: +61 (0) 2 9209 4037

Email: clinicaltrials@claritypharmaceuticals.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostate Cancer

• A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
• A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
• Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
• A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
• Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland

Explore by condition: All Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.